Diaceutics Plc reports 22% H1 revenue growth; Boosts recurring income
LONDON: Diaceutics PLC (AIM: DXRX), a technology provider for pharmaceutical and biotech companies, announced strong first-half revenue growth driven by increased demand for its precision medicine commercialization services. Revenue rose 22% on a constant currency basis to £14.6 million ($18.9 million) in H1 2025, marking a three-year compound annual growth rate of 25%. Recurring revenue…